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Individual epigenetic status of the pathogenic
D4Z4 macrosatellite correlates with disease in
facioscapulohumeral muscular dystrophy
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Chi Yan1,4, Charles P Emerson Jr1,2, Jeffrey B Miller3, Kathryn R Wagner2,5 and Peter L Jones1,2*
Abstract
Background: Both forms of facioscapulohumeral muscular dystrophy (FSHD) are associated with aberrant
epigenetic regulation of the chromosome 4q35 D4Z4 macrosatellite. Chromatin changes due to large deletions of
heterochromatin (FSHD1) or mutations in chromatin regulatory proteins (FSHD2) lead to relaxation of epigenetic
repression and increased expression of the deleterious double homeobox 4 (DUX4) gene encoded within the distal
D4Z4 repeat. However, many individuals with the genetic requirements for FSHD remain asymptomatic throughout
their lives. Here we investigated family cohorts of FSHD1 individuals who were either affected (manifesting) or
without any discernible weakness (nonmanifesting/asymptomatic) and their unaffected family members to
determine if individual epigenetic status and stability of repression at the contracted 4q35 D4Z4 array in myocytes
correlates with FSHD disease.
Results: Family cohorts were analyzed for DNA methylation on the distal pathogenic 4q35 D4Z4 repeat on
permissive A-type subtelomeres. We found DNA hypomethylation in FSHD1-affected subjects, hypermethylation in
healthy controls, and distinctly intermediate levels of methylation in nonmanifesting subjects. We next tested if
these differences in DNA methylation had functional relevance by assaying DUX4-fl expression and the stability of
epigenetic repression of DUX4-fl in myogenic cells. Treatment with drugs that alter epigenetic status revealed that
healthy cells were refractory to treatment, maintaining stable repression of DUX4, while FSHD1-affected cells were
highly responsive to treatment and thus epigenetically poised to express DUX4. Myocytes from nonmanifesting subjects
had significantly higher levels of DNA methylation and were more resistant to DUX4 activation in response to epigenetic
drug treatment than cells from FSHD1-affected first-degree relatives containing the same contraction, indicating that the
epigenetic status of the contracted D4Z4 array is reflective of disease.
Conclusions: The epigenetic status of the distal 4qA D4Z4 repeat correlates with FSHD disease; FSHD-affected subjects
have hypomethylation, healthy unaffected subjects have hypermethylation, and nonmanifesting subjects have
characteristically intermediate methylation. Thus, analysis of DNA methylation at the distal D4Z4 repeat could be
used as a diagnostic indicator of developing clinical FSHD. In addition, the stability of epigenetic repression upstream
of DUX4 expression is a key regulator of disease and a viable therapeutic target.
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DNA methylation
* Correspondence: Peter.Jones@umassmed.edu
1Department of Neurology and Department of Cell and Developmental
Biology, The Wellstone Program, University of Massachusetts Medical School,
55 Lake Avenue North, Worcester, MA 01655, USA
2The Eunice Kennedy Shriver National Institute of Child Health and Human
Development, Sen. Paul D. Wellstone Muscular Dystrophy Cooperative
Research Center, 31 Center Drive, Bethesda, MD, USA
Full list of author information is available at the end of the article
© 2015 Jones et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Jones et al. Clinical Epigenetics  (2015) 7:37 
DOI 10.1186/s13148-015-0072-6
Background
Facioscapulohumeral muscular dystrophy (FSHD) has
long been characterized as an autosomal dominant
genetic myopathy [1-3]; however, the critical role of
epigenetic regulation in both forms of FSHD is now being
recognized, and FSHD can accurately be characterized as
an epigenetic disease [4-8]. FSHD is the most prevalent
(affecting approximately 1:7,500 to 15,000 individuals)
myopathy that indiscriminately afflicts children and
adults of all ages and both genders [1,7,9,10]. FSHD1
(OMIM 158900) accounts for >95% of reported cases
and results from a range of large DNA deletions within
the 4q35 localized macrosatellite D4Z4 repeat array
[11,12]. Healthy, genetically unaffected individuals are
defined as having more than 10 D4Z4 repeat units
(RUs) on both 4q chromosome arms (generally 25 to
35 RUs and as high as 120 RUs per array [13,14]),
whereas individuals with genetic FSHD1 have between
1 and 10 D4Z4 RUs on one 4q chromosome arm, thus
classifying FSHD as an autosomal dominant disease.
These polymorphic FSHD1-sized D4Z4 contractions
by themselves are not pathogenic, and development of
FSHD also requires a disease-permissive allele of the
chromosome 4q subtelomere (4A) in cis with the
contracted array [14-17]. The far less common form,
FSHD2 (OMIM 158901), presents with similar clinical
features as FSHD1 but does not involve contraction of the
D4Z4 array [4,18]. FSHD2 is, however, still genetically
linked to the 4q35 region by the requirement of at least
one permissive 4A-type subtelomere in order to develop
disease [4,17].
Each of the D4Z4 RUs within the 4q35 macrosatellite
contains 3.3 kb of highly GC-rich (73%) DNA, encom-
passing >16 nucleosomes, with multiple repeat sequences
normally associated with heterochromatin [19]. Thus,
FSHD1-sized deletions remove a substantial amount of
regulatory heterochromatin from the 4q35 region, sig-
nificantly altering the local epigenetic landscape of the
contracted allele [20-22]. FSHD2 is also caused by the
epigenetic disruption of the 4q35 D4Z4 array leading
to aberrant gene expression; however, the dysregula-
tion is not caused by the physical removal of regulatory
heterochromatin as in FSHD1 but is due to mutations
in gene(s) encoding the epigenetic machinery respon-
sible for establishing and maintaining repression of the
D4Z4 array [4,5]. More than 85% of FSHD2 cases analyzed
to date are linked to mutations in the SMCHD1 gene
[5,23-25], which encodes a chromatin remodeling protein
required for normal DNA methylation levels and tran-
scriptional repression at certain loci, including D4Z4 arrays
[26-28]. In addition, mutations in the SMCHD1 gene
increase the severity of FSHD1 [6,29], indicating that
SMCHD1 is an epigenetic modifier of both forms of
FSHD. Thus, epigenetic dysregulation of the 4q35
D4Z4 array, albeit through different mechanisms, links
FSHD1 and FSHD2 [4,7,8].
A consequence of the epigenetic disruption at 4q35
in FSHD1 and FSHD2 is the increased expression and
altered splicing of the double homeobox 4 (DUX4) gene
to generate the DUX4-fl (DUX4-full length) mRNA in
FSHD skeletal muscle, which results in aberrant expres-
sion of DUX4-FL and its downstream target genes with
consequent pathology [17,30-36]. Although a copy of
DUX4 resides within each RU of the D4Z4 array [37], only
DUX4-fl transcribed from the distal-most 4q35 D4Z4
repeat is stably expressed in FSHD due to the presence
of a polyadenylation signal (PAS) in a permissive 4A
subtelomere-specific exon distal to the array, which is
absent in 4B and other non-permissive subtelomeres
[17]. This distal third exon is spliced into the mRNA
(thereby explaining the linkage of FSHD to the 4A-type
subtelomeres) and translated to produce DUX4-FL pro-
tein [17,30]. However, DUX4-FL expression in FSHD is
very low and shows cell-to-cell variability as <0.5% of
the nuclei in FSHD1-derived myogenic cultures express
DUX4-FL [30,33]. Although restricted to a small percent-
age of myonuclei at any one time, the aberrant expression
of DUX4-FL is proposed to lead to progressive muscle at-
rophy and ultimately FSHD pathology [30-36,38-41]. Two
studies have also reported expression of DUX4-fl mRNA
and protein in some myogenic cells and muscle tissue from
certain asymptomatic and healthy individuals [33,42], al-
though at lower levels than in FSHD1 patients. Thus,
DUX4-fl expression per se is not sufficient for developing
clinical FSHD, suggesting the existence of disease modifiers
both upstream and downstream of DUX4-FL.
As described above, one important class of disease
modifier encompasses chromatin regulatory proteins,
such as SMCHD1, that function to establish or maintain
epigenetic repression of the D4Z4 array, thus affecting
DUX4-fl expression. In addition, contracted D4Z4 arrays
may be marked by different epigenetic states in different
individuals due to shifts in the probabilistic establish-
ment of these states during development, similar to the
characteristics of metastable epialleles (reviewed in [43,44]).
To investigate the role of epigenetic modifications in FSHD,
we analyzed patterns of DNA methylation at the 4q35
D4Z4 array in family cohorts of myogenic cells from
FSHD1-affected subjects, FSHD1-nonmanifesting carriers,
and healthy controls. We determined that these cells have
individual differences at the 4q35 D4Z4 array and these
epigenetic differences affected the stability of DUX4 silen-
cing. The patterns of DNA methylation at the distal, patho-
genic D4Z4 repeat, as well as inducibility of DUX4-fl
expression following epigenetic drug treatment, correlated
with disease manifestation and offer an explanation for
how individuals can be genetically FSHD1 yet clinically
asymptomatic.
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Results
There are several key distinguishing aspects of our ana-
lysis. We studied our well-characterized FSHD1 family
cohorts of myogenic cells derived from muscle biopsies
[33,45,46], thus minimizing differences related to genetic
background and also allowing the analysis of multiple
cohorts of FSHD1-affected subjects and nonmanifesting
carriers containing the same D4Z4 contraction. FSHD is
a myopathy, and DUX4-fl expression is induced in dif-
ferentiated myogenic cells [47]; thus, the use of these
cells, as opposed to the lymphocytes used in most other
studies, allowed analysis of epigenetic status and patho-
genic gene expression in the most affected cell type. In
contrast to earlier studies which analyzed very few
CpGs, our study used bisulfite sequencing (BSS), enab-
ling analysis of the methylation status for >50 CpGs each
in both the gene body and 5′ promoter region of DUX4
[48]. Importantly, our BSS amplifications were specific
to the 4qA D4Z4 (4qA and 4qA-L BSS assays) or the 4q
and 10q D4Z4 RUs (DUX4 5′ BSS assay). Our assays did
not amplify and assess the numerous D4Z4 homologs
from other regions of the genome that are not associated
with or epigenetically dysregulated in FSHD [48,49].
Finally, we specifically analyzed the pathogenic distal-
most D4Z4 repeat for both DNA methylation status
and stability of epigenetic repression as indicated by
DUX4-fl expression. This is in contrast to most other
studies which have analyzed four centromere-proximal
D4Z4 repeats (two from 10q, one from the contracted
4q, and one from the non-contracted 4q); these studies
do not specifically assess the pathogenic chromosome
and they focus on a region far from the site of stable
DUX4-fl expression [25]. Our unique approach provides
the first epigenetic analysis of the distal DUX4 gene as-
sociated with FSHD and identifies distinct epigenetic
characteristics of healthy, FSHD1-affected, and FSHD1-
nonmanifesting states.
The frequency of DUX4-FL expression is stable in culture
Myogenic cells obtained from different individual donors
have large differences in the frequency of DUX4-FL pro-
tein expression [33]. Therefore, we first determined if
DUX4-FL levels in myogenic cells were stable upon re-
peated culturing. Our earlier study [33] raised the pos-
sibility that DUX4-FL expression frequencies differed
depending on the donor; however, that study examined
DUX4-FL protein in only one culture for most donors
and did not determine if the number of population
doublings affected DUX4-FL expression. In addition,
DUX4-FL expression in myogenic cells is almost exclu-
sive to differentiated myocytes, as identified by expres-
sion of myosin heavy chain (MyHC) [47]; our previous
study reported the number of DUX4-FL-positive nuclei
per 1,000 total nuclei in the cultures and thus did not
account for possibly differing extents of differentiation
among different cultures. Thus, to extend our previous
study, we examined DUX4-FL expression frequencies
at different population doublings (PD) using a serial
subculturing assay (see the ‘Methods’ section) with dif-
ferentiated FSHD and unaffected cells derived from
the biceps or deltoid muscles of multiple individual do-
nors (Additional file 1: Table S1). Upon repeated sub-
culturing, we found that the doubling times of these
primary cultures in growth medium began to slow by PD
Table 1 DUX4-FL expression in differentiated myogenic cell cultures by individual donor and muscle of origin
Family Donor EcoRI/BlnI fragment sizes Disease status #DUX4-FL + nuclei per 1,000 nuclei in MyHC + cells (average ± SE (n))
Biceps-derived (bic) Deltoid-derived (del)
07 07A 29 kb 4A161 FSHD manifesting 0.095 ± 0.028 (14)** 0.17 ± 0.09 (4)
53 kb 4A161
07U 34 kb 4B163 Unaffected 0.00 ± 0.00 (14)** 0.015 ± 0.015 (4)
53 kb 4A161
09 09A 25 kb 4A161 FSHD manifesting 0.79 ± 0.21 (14)** 2.14 ± 0.84 (4)*
>112 kb 4B168
09U >112 kb 4A161 Unaffected 0.12 ± 0.08 (14)** 0.00 ± 0.00 (4)*
>112 kb 4A166H
17 17A 19 kb 4A161 FSHD manifesting 3.71 ± 0.63 (14)** 4.76 ± 0.97 (4)**
87 kb 4A-L161
17U 97 kb 4B163 Unaffected 0.021 ± 0.015 (12)** 0.012 ± 0.012 (4)**
>112 kb 4A161
17 V 90 kb 4A161 Unaffected 0.00 ± 0.00 (7)** n.d.
>112 kb 4B168
*P < 0.05, **P < 0.01 by t-test for FSHD vs. unaffected within the indicated family. n.d. = not done.
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approximately 55 to 60, therefore we limited DUX4-FL
expression experiments to differentiated cultures derived
from myogenic cells at PD ≤ ~47, which was prior to the
replicative limit.
Differentiated cells from three FSHD donors showed
an almost 50 times difference in average frequency of
DUX4-FL expression, with the frequency of DUX4-FL-
positive nuclei per 1,000 nuclei in myosin-expressing
cells ranging from approximately 0.1 (for 07Abic cultures)
to approximately 4.7 (for 17Adel cultures) (Table 1). In
addition, DUX4-FL expression frequencies were approxi-
mately equal for the biceps- and deltoid-derived cultures
for each donor (Table 1). We noted that DUX4-FL expres-
sion frequencies in these three cohorts inversely correlated
with D4Z4 array length as measured by EcoRI-BlnI re-
striction fragment length (Table 1 and Additional file 1:
Table S1), which, despite the limited sample size, is po-
tentially intriguing considering short 4q D4Z4 arrays
(<5 RUs) are associated with severe FSHD disease while
longer arrays show more inter-individual variation in
clinical severity [20,25]. For these three FSHD donors,
cultures of biceps-derived (Abic) and deltoid-derived
(Adel) myogenic cells from 17A consistently had the
highest frequencies of DUX4-FL expression, whereas
cells from 09A typically had intermediate levels, and
cells from 07A typically had the lowest level of DUX4-FL
expression (Figure 1). Thus, FSHD cells obtained from dif-
ferent donors maintained consistently different frequen-
cies of DUX4-FL expression upon repeated sub-culturing
and over a range of total population doublings. For cells
from each of three FSHD donors, the frequency of DUX4-
FL-positive nuclei showed a weak trend to lower fre-
quency of expression at higher passages and population
doublings (R2 = 0.16 for 07Abic, 0.32 for 09Abic, and 0.39
for 17Abic).
Consistent with our earlier work [33], we also detected
a low frequency of DUX4-FL expression in nuclei within
differentiated (MyHC-positive) cells from two of the four
healthy (non-FSHD) donors (Table 1). Cells from these
two unaffected donors showed a weak trend to higher
DUX4-FL expression after repeated subculturing (R2 = 0.31
for 09Ubic and 0.26 for 17Ubic). As with our previous
study investigating DUX4-FL expression in large single cul-
tures of myogenic cells from nine of the Wellstone Center
cohorts (03, 07, 09, 12, 15, 16, 17, 18, 20) [33], for each of
the three donor families (07, 09, 17), the average frequency
of DUX4-FL-expressing nuclei was higher in differentiated
cells from the FSHD donor than from the unaffected donor
across multiple cultures (Table 1, n = 4 to 14); this differ-
ence reached significance (P < 0.05, t-test) in every case
except 07Adel vs. 07Udel (P < 0.15) (Table 1). Thus,
the percentage of myonuclei that expressed DUX4-FL
varied among cell cultures isolated from different indi-
viduals but remained relatively stable among different
cultures derived from the same donor biopsy. In cultures
from all individuals tested, derived from 13 different biopsies,
the number of DUX4-FL expressing nuclei remained stable
Figure 1 Myogenic cells from different individuals have consistently
different and stable frequencies of DUX4-FL expression. (A)
Myogenic cells from different individuals have different extents of DUX4-FL
expression. DUX4-FL expression frequency (number of DUX4-FL-positive
nuclei per 10,000 nuclei in myosin-positive cells) was measured in multiple
independent cultures of differentiated myogenic cells from three FSHD
patients (07Abic, 09Abic, and 17Abic; red) and their unaffected (control)
family members (07Ubic, 09Ubic, 17Ubic, and 17Vbic, respectively;
green). Within each family, FSHD cells had a significantly higher
frequency of DUX4-FL expression than control cells (P < 0.01; t-tests;
n = 12 to 14). DUX4-FL expression frequencies of cells from each
FSHD patient also differed significantly from each other, with
17Abic > 09Abic > 07Abic (P < 0.01; t-tests; n = 12 to 14). Red
open diamonds = FSHD; green open diamonds = unaffected control;
horizontal bar = average; average ± SE and ‘n’ are shown below each
culture name. (B) DUX4-FL expression frequency does not show a clear
change upon serial subculture. Cultures of cells from the same FSHD
and controls as in (A) were serially subcultured through 6-7 passages,
and DUX4-FL expression frequency was measured at each passage in
differentiated cultures as described in the ‘Methods.’ Each point (closed
red squares for FSHD, closed green circles for controls) shows results
for a single passage, with the passage number increasing from left to
right in sequence. The beginning and ending number of total
population doublings (PD) for each cell strain is shown below the
name (e.g., for 07Abic, the cells were first examined at PD = 28
and these reached PD = 47 at the final passage examined).
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upon repeated subculturing, indicating that the mechanisms
regulating DUX4-FL expression are similarly stable in
myocyte cell culture.
Myogenic cells derived from FSHD1-affected subjects are
significantly hypomethylated at the distal D4Z4 unit of a
contracted 4q array compared with the non-contracted
allele and healthy controls
Overall DNA methylation levels of the 4q35 D4Z4 repeat
array differ significantly between healthy cells, which are
hypermethylated (>50% methylation of assayed restriction
enzyme sites) on both 4q alleles, and cells derived from
FSHD1-affected subjects, which are comparatively hypo-
methylated (<35% methylation of assayed restriction en-
zyme sites) on the contracted 4q allele [4,20,50]. While an
earlier study found no significant correlation between dis-
ease severity and methylation among FSHD1-affected sub-
jects [20], it did suggest that hypomethylation may, like
disease severity, be more pronounced for those subjects
with shorter D4Z4 arrays. As mutations in the chromatin
regulator SMCHD1 can increase clinical severity in FSHD1
families [6,29], it is likely that the overall epigenetic state of
the 4q35 D4Z4 array can affect the clinical phenotype, even
when taking D4Z4 array length into account. Of note, pre-
vious reports on FSHD1 DNA methylation assayed only a
few CpGs in methylation-sensitive restriction sites either in
rare genotypes [20,50] or in a combined analysis of the
most centromeric D4Z4 repeat of both 4q and 10q chro-
mosomes as a proxy for the epigenetic status of the array
[4,25], or analyzed all 4q and 10q D4Z4 RUs as a group
(Figure 2) [51]. In particular, one recent epigenetic study
did not distinguish the contracted chromosome from the
three other non-pathogenic chromosomes [51]. Another
study used global estimates of methylation as a func-
tion of D4Z4 repeat lengths to detect deviation from
predicted average methylation [25], which requires complete
Figure 2 Specific DNA methylation analysis of the FSHD-associated distal 4q D4Z4 repeat unit on A-type subtelomeres by BSS
sequencing. (A) Schematic representations of D4Z4 arrays on 4q and 10q chromosomes. Healthy unaffected individuals have any
combination of two of the non-contracted 4q chromosomes; FSHD1 is not associated with 4qB or 10qA chromosomes. FSHD1-affected
and nonmanifesting subjects have at least one contracted 4qA array and are distinguished clinically by disease presentation. The regions
assayed by BSS are indicated as follows: 4qA BSS assay (blue bars), 4qA-L BSS assay (orange bars), and DUX4 5′ BSS assay (green bars). B = BsaAI
and F = FseI restriction sites often used for DNA methylation analysis. (B) Schematic of the distal 4qA (upper) and 4qA-L (lower) D4Z4 RUs analyzed in
this study. Black arrows indicate PCR primer locations and red Xs indicate five sequence changes between 4A and 10A within the primers. Rare 10qA
products can be amplified in the 4qA BSS assay if PCR primers degrade; however, these are clearly identified by sequence polymorphisms (purple Xs)
and removed from analysis.
Jones et al. Clinical Epigenetics  (2015) 7:37 Page 5 of 22
knowledge of genotype and cannot ascribe deviation from
the predictions to any particular allele. Regardless of the
chosen method, all previous studies failed to capture the epi-
genetic status of the pathogenic distal D4Z4 repeat on the
contracted FSHD1 allele [4,20,25,50-52], which may differ
between genetically FSHD1 individuals. Considering the
stable differences in the number of DUX4-FL expressing
myonuclei among cultures from FSHD1-affected subjects,
we therefore investigated the DNA methylation profiles of
the distal D4Z4 repeat on healthy and FSHD1 alleles and
assessed the stability of epigenetic repression in myocytes at
the 4q35 D4Z4 array using DUX4-fl mRNA expression as a
read-out for chromatin relaxation. To further address poten-
tial connections to FSHD1 disease severity, without the con-
founding effects of 4qA contraction length or haplotype, we
also analyzed familial nonmanifesting carriers of FSHD1-
sized contractions.
We developed two BSS assays specific for analyzing
the DNA methylation status of the distal D4Z4 on 4qA
chromosomes (Figure 2 and [48]) by utilizing polymor-
phisms in the primers that are exclusive to 4A and not
found in 10A or 4B [17]. The 4qA BSS assay analyzes 56
CpGs in the distal D4Z4 RU on 4qA-containing chro-
mosomes, as diagrammed in Figure 2B. A fraction of
chromosomes characterized as 4qA are actually an allelic
variant termed 4qA-L; these contain an additional 2 kb
of D4Z4 sequence at the distal repeat, resulting in a
much larger DUX4 intron 2, while the distal exon 3 and
A-type subtelomere are unchanged. Thus, the 4qA-L
BSS assay utilizes the same 4A-specific reverse BS-PCR
primers as the 4qA assay but analyzes a distinct set of
30 CpGs in the distal repeat on 4qA-L chromosomes.
For comparisons with our 4qA and 4qA-L BSS analyses,
as well as with other published studies [51,52], we de-
signed a BSS analysis upstream of the DUX4 open read-
ing frame (DUX4 5′ BSS assay, Figure 2), which analyzes
the methylation status of 59 CpGs. This DUX4 5′ region
is amplified exclusively from all 4q/10q-type D4Z4 RUs,
not from other D4Z4 homologs [49], and encompasses a
putative CTCF binding site and the DR1 region that is
hypomethylated in all 4q/10q D4Z4 RUs in FSHD2 cells
[52,53]. It was critically important that we found these
BSS assays to be specific to 4q (4qA and 4qA-L BSS
assays) or 4q/10q D4Z4s (DUX4 5′ BSS assay), as indi-
cated by the >99.8% coverage of expected CpGs when com-
pared to the reference sequences (Figures 3, 4, 5, and 6;
Additional file 1: Figures S1 and S2), because there are
D4Z4 homologs on chromosomes 3, 13, 14, 15, 21, 22, and
Y which do not show epigenetic changes in FSHD [49].
Fortunately, the 4q and 10q D4Z4s have very high se-
quence conservation and very few polymorphisms, so
even if occasional non-4q/10q D4Z4s were amplified,
they would be readily distinguished by their high de-
gree of sequence polymorphisms and discarded from
analysis [49]. Thus, combining the 4qA/4qA-L BSS
and DUX4 5′ BSS provides a specific and detailed
analysis of DNA methylation patterns at the pathogenic
distal 4qA D4Z4 in the context of overall 4q/10q D4Z4
DNA methylation in FSHD1-affected, nonmanifesting,
and healthy control cells.
We used the BSS assays described above to compare
DNA methylation profiles (Figure 3) in myogenic cells from
eight familial cohorts (03, 07, 09, 12, 16, 17, 19, and 21)
representing clinically affected (manifesting) FSHD1
subjects that showed low (03A, 07A), mid-level (09A),
and high (17A) percentages of DUX4-FL expressing
myonuclei, and healthy controls (U). In addition, we
assayed peripheral blood mononuclear cells (PBMCs)
from three familial cohorts (39, 41, and 51) (Figure 4).
In subjects with only one 4qA allele (Additional file 1:
Table S1), all of the 4qA BSS data was derived from a
single allele. Similarly, in subjects with one 4qA-L allele
(Additional file 1: Table S1), all of the 4qA-L BSS data
was derived from a single allele. In subjects with two
4qA alleles, 50% of the BSS sequences are expected to
originate from each of the two 4q alleles (although the
precise percent may differ due to random sampling
fluctuations). Thus, for FSHD1 subjects, 50% of the se-
quences are expected to originate from the pathogenic
D4Z4 RU and 50% from the non-contracted distal D4Z4
RU. However, to prevent high and variable methylation at
the non-contracted allele from masking or diluting the
signal from the contracted allele, we used a statistical
mixture-model to estimate the average percent methyla-
tion for just the least-methylated of the 4qA or 4qA-L
alleles (see the ‘Methods’ section). As expected, the
cells from unaffected subjects were hypermethylated
(on average 71% methylation across the region for myocytes,
62% for PBMCs) and the cells from 11 FSHD1-affected sub-
jects were hypomethylated (on average 7% for myocytes,
14% for PBMCs). However, despite a >50-fold range in
DUX4-FL expressing myonuclei between the FSHD1
samples (Figure 1 and [33]), there were only small dif-
ferences in average 4qA DNA methylation (03A = 5.8%,
07A= 17.8%, 09A= 6.7%, and 17A= 9.2%) for the contracted
4qA chromosomes analyzed for each subject. BSS ana-
lysis of the DUX4 5′ region supported these results
(Additional file 1: Figure S1). Cells from FSHD1-affected
subjects displayed higher overall average methylation at
the DUX4 5′ region than at the 4qA region, but this is to
be expected because the non-contracted 4q and both 10q
chromosomes are included in analysis of the 5′ region;
moreover, since any D4Z4 repeat (not just the distal-most)
may be amplified in this PCR assay, the contracted
4qA allele makes a proportionately smaller contribu-
tion to the overall methylation.
Overall, in cells from FSHD1-affected subjects, the
contracted 4qA allele is specifically hypomethylated and
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the non-contracted allele remains hypermethylated.
DNA methylation levels at the distal D4Z4 unit are dra-
matically higher for healthy than for FSHD1-affected
cells (P = 2 × 10−12, likelihood ratio test (LRT)), correlating
with the correspondingly lower numbers of DUX4-FL
expressing myonuclei in healthy cells. However, DNA
methylation levels alone do not explain differences in the
number of DUX4-FL expressing myonuclei among cells
from different FSHD1-affected subjects or explain why so
few FSHD1-affected myonuclei in a culture express DUX4-
FL. Since DNA methylation is only one component of the
epigenetic regulation, it is likely that there are additional
differences in the overall chromatin state that can account
for these changes in expression levels and frequency.
Figure 3 DNA methylation levels in myocytes at the distal D4Z4 repeat on the contracted 4qA chromosome correlate with disease.
BSS analysis of the distal pathogenic D4Z4 RU in family cohorts of myogenic cells derived from biceps (cohorts 03, 07, 09, 12, 16, 17, 19, and 21)
of FSHD1-affected (left column) and unaffected (right column) subjects. Overall, 56 predicted CpGs (each represented as a column, numbered 1-56,
left to right) arranged linearly on a chromosome were assayed for the 4qA BSS assay, or 30 predicted CpGs (columns numbered 1-30, left to right) for
the 4qA-L BSS assay, as indicated in the left margin. Each independent chromosome assayed is represented by a row with each CpG represented by a
box (red boxes indicating methylation, blue boxes indicating lack of methylation, and empty boxes indicating lack of a CpG detected at that site).
Importantly, on average >99% of the predicted CpGs were identified in the sequences analyzed for each sample, and each total sequence
had >98% identity to the reference sequence, indicating that the amplified BSS products are specific to 4qA and there are very few polymorphisms.
The haplotypes, associated EcoRI/BlnI fragment sizes, and calculated D4Z4 RUs of the shortest FSHD-permissive allele are listed after sample names taken from
Additional file 1: Table S1; symbols ^ and ^^ are described there. Numbers in the right margin indicate estimated percent methylation for each of two alleles
using a beta-binomial mixture model (allele 1 in red, allele 2 in green), and using a mono-allelic model (orange). The color bar in the right margin indicates
confidence in assignment of each sequence to each allele: pure red for 100% posterior probability for allele 1; pure green for 100% posterior probability
for allele 2; blended colors for intermediate values (color scale in the lower right).
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Myogenic cells from FSHD1-nonmanifesting subjects have
intermediate DNA methylation levels at the distal DUX4
on the contracted 4q allele
The existence of nonmanifesting carriers of FSHD1-sized
4q35 D4Z4 arrays in FSHD1-affected families has been
known for many years, and more recently, a high preva-
lence of D4Z4 array contractions with FSHD-permissive
alleles in the general healthy population has been reported
[33,54-60]. Considering that the 4q35 epigenetic status is
dramatically different between FSHD1-affected and healthy
subjects, we hypothesized that these differences could
account for the different disease outcomes between FSHD1
subjects and relatives possessing the same genetic deletion
but varying manifestations of weakness. Therefore, nine
family cohorts of genetic FSHD1 subjects with manifesting
and nonmanifesting members (Additional file 1: Table S1)
[33] were profiled with the 4qA/A-L BSS analysis, four
using myogenic cells and five using PBMCs (Figures 5
and 6) [33]. Within each family, myocytes from the
nonmanifesting subject(s) had higher estimated D4Z4
DNA methylation arising from the contracted allele than
myocytes from the manifesting subject(s) (Table 2). DNA
methylation analysis of the DUX4 5′ region for four of the
cohorts revealed a similar trend upstream of the gene
body with higher average levels of DNA methylation for
each nonmanifesting subject compared with the familial
manifesting subject (Additional file 1: Figure S2). Thus, des-
pite having the same FSHD1-sized allele, cells from nonma-
nifesting individuals had higher DNA methylation levels
compared with those of manifesting subjects in both the
pathogenic distal DUX4 gene body and the DUX4 pro-
moter regions. In every case, nonmanifesting individuals
were about the same age or much older than their mani-
festing relative (Additional file 1: Table S1), indicating that
increased age does not correlate with loss of methylation.
In summary, higher DNA methylation levels at the distal
4q35 D4Z4 unit on the contracted 4qA allele were signifi-
cantly correlated with decreased FSHD disease severity in
Figure 4 DNA methylation levels in PBMCs at the distal D4Z4 repeat on the contracted 4qA chromosome correlate with disease.
BSS analysis (as described in Figure 3) of the distal pathogenic D4Z4 RU in family cohorts of PBMCs derived from blood of FSHD1-affected
(left column) and healthy unaffected (right column) subjects. Refer to the Figure 3 legend for additional details and descriptions.
Figure 5 FSHD1-affected subjects have lower DNA methylation levels in myocytes at the distal pathogenic D4Z4 repeat than
nonmanifesting relatives. BSS analysis (as described in Figure 3) of the distal pathogenic D4Z4 RU in family cohorts of myogenic cells from
FSHD1-affected (left column) and FSHD1-nonmanifesting (right column) subjects. As in Figure 3, on average >99% of the predicted CpGs for the
4qA D4Z4 region were identified in the sequences analyzed for each sample, indicating that the amplified BSS products are specific to 4qA. Refer
to the Figure 3 legend for additional details and descriptions.
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individuals who shared the same FSHD1 deletion (P = 0.004
by a nonparametric sign test, for any choice of which sub-
ject to include for the two cases of two affected or two non-
manifesting subjects in a family). This increased level of
DNA methylation in nonmanifesting vs. manifesting sub-
jects was also significant in a parametric linear mixed-
effects analysis (see the ‘Methods’ section), in which levels
for nonmanifesting carriers of FSHD1 contractions are
slightly but significantly higher than for manifesting sub-
jects (P = 0.02, LRT), but significantly lower than for healthy
controls (P = 1 × 10−7, LRT). Notably, there was no signifi-
cant difference between myogenic cells and blood cells
(P = 0.53, LRT), which makes blood samples appealing as a
less-invasive alternative to muscle biopsies, at least for stud-
ies of DUX4 methylation.
We conclude that, with respect to the pathogenic distal
D4Z4 repeat on the contracted 4qA allele (when appropri-
ate), healthy subjects display DNA hypermethylation,
FSHD1 subjects manifesting weakness display hypomethy-
lation, and FSHD1-nonmanifesting subjects display inter-
mediate levels of methylation, slightly but significantly
higher than those of FSHD1-affected subjects.
Stability of epigenetic repression is variable between
myogenic cells derived from FSHD1-affected and
nonmanifesting subjects
In myogenic cell cultures, cells from FSHD1-affected subjects
have a very small percentage of nuclei (1:300 to 1:10,000) that
express detectable levels of DUX4-FL protein (Figure 1), and
levels of DUX4-fl mRNA are extremely low [30,33]. How-
ever, virtually all D4Z4-contracted chromosomes analyzed
from FSHD1-affected subjects showed robust DNA hypome-
thylation (Figures 3, 4, 5, 6, and 7), indicating that epigenetic
repression of DUX4 expression (or stability) is still main-
tained in the vast majority of myonuclei. Since chromatin
states are complex and DNA methylation levels are only one
indication of the local chromatin environment, we asked if
there were differences in the stability of D4Z4 repression in
our family cohorts. To interrogate the epigenetic repression
of the 4q35 D4Z4 arrays, cultures of myogenic cells were
treated with 5-aza-2′-deoxycytidine (Decitabine/ADC) [61]
and/or Trichostatin A (TSA) [62] and DUX4-fl mRNA
expression was assayed by qRT-PCR (Figures 8 and 9).
Decitabine treatment directly leads to decreases in DNA
Figure 6 FSHD1-affected subjects have lower DNA methylation levels in PBMCs at the distal pathogenic D4Z4 repeat than
nonmanifesting relatives. BSS analysis (as described in Figure 3) of the distal pathogenic D4Z4 RU in family cohorts of PBMCs from FSHD1-affected
(left column) and FSHD1-nonmanifesting (right column) subjects. Refer to the Figure 3 legend for additional details and descriptions.
Table 2 Comparison of percent DNA methylation between
cells derived from FSHD1-affected and nonmanifesting
familial cohorts
Cohort Manifesting
(%)
Nonmanifesting
(%)
EcoRI/BlnI
(kb)
D4Z4
RU*
15 15.2 25.4 28 8
28 14.6 25.2 29 8
29 6.5 12.5 30 8.5
30 10.6 32.6 30 8.5
43 14.2 15.5 19 5
46 13.7 27.6 22 6
47 9.3 14.9 and 16.9 30 8.5
48 7.3 and 4.9 11.7 21 6
49 8.0 18.8 22 6
Comparison of percent DNA methylation using the 4qA BSS assay. *Calculated
as D4Z4 RU = (EcoRI/BlnI fragment kb − 2 kb)/3.3 [15].
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methylation levels [61,63] and, at certain loci, indirectly
causes the reduction of repressive histone marks and the es-
tablishment of a permissive chromatin environment marked
by nucleosome depletion and histone acetylation [64-66].
TSA is a broad-spectrum histone deacetylase (HDAC) in-
hibitor that can alter chromatin content by blocking the re-
moval of acetyl groups from histones (and other acetylated
non-histone targets) and inhibiting recruitment of some het-
erochromatin proteins [62,67,68]. Treatment with either
Decitabine or TSA relieves epigenetic repression of certain
loci, leading to gene activation [69,70], and the combination
of the two drugs can have a synergistic effect [71]. We tested
whether treatment with these small molecule enzyme inhibi-
tors might decrease the repressive chromatin content of the
D4Z4 array and potentially affect DUX4-fl expression levels.
As seen previously for DUX4-FL protein expression
(Figure 1), initial DUX4-flmRNA levels for the five cohorts
analyzed were variable among the FSHD1 cells, while
Figure 7 Summary of DNA methylation data. (A) A plot of the DUX4 gene body estimated average percent methylation for each sample, using
a mixture-model to estimate this value for the 4qA allele with the lesser percent. FSHD-affected samples are split into two groups, those with
nonmanifesting first-degree relatives in the sample cohort (FSHD(b); orange) and those without (FSHD(a); red). The nonmanifesting samples are
labeled NonMfst (green), and the unaffected control samples are labeled Control (grey). Solid symbols indicate myocyte samples, and empty
symbols indicate blood samples. Triangles indicate data from the 4qA assay and squares indicate data from the 4qA-L assay. Each group is subdivided
into myocyte and blood subgroups. Within each of the eight subgroups, symbols are ordered by family number. Blue crosses behind each subgroup
indicate means ± standard errors based on a linear mixed effect (LME) model with fixed effects for each of these eight subgroups, an additive fixed
effect for assay type, and a random effect for family. Means and error bars show estimated fixed effects for 4qA assay; 4qA-L estimates are higher. LME
calculations were performed on logit-transformed methylation probabilities, and results were then transformed back to percentages using a logistic
transformation (which is why the error bars are not symmetric about the means). (B) The same data as in (A), with the same color scheme, but with
samples ordered by minimum 4qA EcoRI/BlnI length (ordered by family number in case of ties) and with lines connecting related subjects. Vertical
green lines connect FSHD-affected and nonmanifesting pairs (who have the same minimum 4qA EcoRI/BlnI length), and dashed grey lines connect
FSHD-affected and control pairs (who do not). Vertical green line is not visible for family 43 (fourth column).
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healthy control cells expressed DUX4-fl at much lower
levels. FSHD1-affected and control cells were treated
with Decitabine, TSA, or both, and DUX4-fl expression
was assayed by qRT-PCR (Figure 8). DUX4-fl was detected
in FSHD1-affected cells from both cohorts and, at much
lower levels, in healthy controls, consistent with our
previous study [33]. Surprisingly, Decitabine treatment
of healthy cells, which are hypermethylated at the 4q35
D4Z4 array, only mildly induced DUX4-fl levels and
the absolute levels never approached those found in
Decitabine-treated cells from FSHD1-affected subjects
(Figure 8). Similarly, treatment with TSA had no
effect on DUX4-fl levels in any of the healthy con-
trols. Interestingly, the combination of Decitabine and
TSA treatment had a small effect on induction in two of
the five healthy lines (09U, 4.7-fold; 07U, 10.2-fold); how-
ever, again, the resulting DUX4-fl levels were well below
those of the treated cells from all five FSHD-affected sub-
jects (Figure 8). To control for efficacy of drug treatment,
we assayed the expression of the ankyrin repeat domain 1
(ANKRD1) gene, which is known to be epigenetically
regulated in myocytes [72], and found that Decitabine/
TSA treatment significantly induced its expression equally
in both unaffected and affected cells (Additional file 1:
Figure 8 Myocytes from FSHD1-affected subjects are epigenetically poised to express DUX4-fl. Myocytes from five family cohorts (03, 07,
09, 17, and 19) of clinically affected FSHD1 subjects (A) and healthy first-degree relative controls (U) were treated in parallel with Decitabine
(ADC), TSA, ADC + TSA (ADC TSA), or left untreated (NT). DUX4-fl expression was analyzed by qRT-PCR and normalized to levels of 18S RNA. Data
are plotted as fold expression relative to the untreated control sample for each cohort and summarized in the table, lower right. All assays were
repeated three times and each qRT-PCR was performed in triplicate.
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Figure S6). Thus, with respect to DUX4-fl expression,
healthy control cells are refractory to these epigenetic
drug treatments, suggesting that normal repression of
the non-contracted D4Z4 array is very stable.
Conversely, Decitabine treatment of FSHD1-affected
cells, which are already hypomethylated compared with
controls at the distal D4Z4 RU (Figures 3 and 4), signifi-
cantly induced DUX4-fl in four of the five subjects (03A,
50-fold; 07A, 120-fold; 17A, 3.2-fold; 19A, 122-fold) with
three of the five showing >50-fold induction. The lone
cell line (09A) that did not show induction by Decitabine
had the highest levels of DUX4-fl mRNA in the untreated
sample, and >40-fold more than its corresponding control
cell line (09U), suggesting that these cells may have already
reached the maximum level of epigenetic relaxation at-
tainable. Of the five cohorts, only 03A, which expressed
the lowest levels of DUX4-fl of all the untreated FSHD-
affected cells, showed induction by TSA alone. We con-
clude that myogenic cells from FSHD1-affected subjects
have less stable epigenetic repression of DUX4 than their
healthy counterparts, and although the majority of cells
do not express DUX4-fl, they are epigenetically poised for
DUX4-fl expression.
Similarly, four family cohorts of myogenic cells from
FSHD1-affected and nonmanifesting subjects were assayed
for their response to Decitabine and/or TSA treatment
(Figure 9). Again, Decitabine induced DUX4-fl expression
in cells from FSHD1 individuals manifesting weakness in
all four cohorts (15A, 28A, 29A, and 30A), while TSA
alone had little to no effect. For 29A, the combination of
Decitabine and TSA synergistically induced DUX4-fl ex-
pression. In parallel, cells from familial nonmanifesting
subjects were subjected to the same set of drug treatments
and assayed for DUX4-fl expression. For cells from
Figure 9 Myocytes from FSHD1-nonmanifesting subjects are more refractory to expressing DUX4-fl than myocytes from FSHD1-
affected relatives. Myocytes from four family cohorts (15, 28, 29, and 30) of FSHD1-affected subjects (black bars, ‘A’ subjects) and FSHD1-
nonmanifesting subjects (gray bars, ‘B’ subjects) were treated in parallel with Decitabine (ADC), TSA, chaetocin (CH), or combinations of drug
treatments, as indicated. DUX4-fl expression was analyzed by qRT-PCR, normalized to levels of 18S RNA, and plotted as fold expression compared
to the untreated samples for each cell strain. Comparisons were between FSHD1-affected and FSHD1-nonmanifesting for each treatment
(*P < 0.05; **P < 0.01, ***P < 0.001, Student’s t-test). All assays were repeated three times and each qRT-PCR was performed in triplicate.
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nonmanifesting subject 29B, the pattern of induction was
similar, although less pronounced, to that for cells from
FSHD1 subject 29A. However, cells from nonmanifesting
subjects 15B, 28B, and 30B showed little to no response to
Decitabine or TSA, either alone or in combination.
In addition to FSHD-dependent changes in DNA
methylation and histone acetylation states, changes in
histone methylation at the FSHD locus have also been
reported. These changes include reduced histone H3
lysine 9 tri-methylation (H3K9me3) and loss of its binding
protein, heterochromatin protein 1 (HP1) [21,49]. Redu-
cing the levels of H3K9me3 with chaetocin (CH), an in-
hibitor of the SUV39H1 methyltransferase responsible for
establishing H3K9me3, induces DUX4-fl expression in im-
mortalized human KD3 myoblasts [49,73,74]. Therefore,
we assessed DUX4-fl induction by CH in these cohorts of
FSHD-affected and nonmanifesting cells (Figure 9). Simi-
lar to treatment with Decitabine, treatment with CH alone
induced DUX4-fl expression, and the combination of both
increased expression even further. Again, for each treat-
ment, cells from FSHD1 subjects manifesting weakness
had higher DUX4-fl levels than cells from their nonmani-
festing relatives with the identical 4qA allele. Thus, the re-
pression of DUX4-fl in cells from nonmanifesting carriers
is more refractory to induction by epigenetic drugs than
in cells from their clinically affected relatives, despite shar-
ing the same D4Z4 contraction.
Discussion
Patterns of DNA methylation at the pathogenic D4Z4
correlate with disease outcome in FSHD and can distinguish
between FSHD1-affected, FSHD1-nonmanifesting, and
healthy controls
Studies investigating FSHD1 families have identified asymp-
tomatic individuals that share the same FSHD1 genetic diag-
nosis as their affected relatives yet report no noticeable
muscle weakness [25,33,54,56-58]. Similarly, larger studies
of normal individuals with no known FSHD relatives re-
vealed that there are many individuals - reportedly approxi-
mately 1% to 3% of certain populations - that fit the current
FSHD1 genetic diagnostic criteria yet show no clinical mani-
festation of the disease [60,75]. It is established that the over-
all epigenetic status of the 4q35 D4Z4 macrosatellite is
distinctly altered between FSHD-affected and healthy con-
trol subjects [4,20,21,49,50,76]. Therefore, we hypothesized
that epigenetic changes, including DNA methylation at the
4q35 D4Z4 array and stability of epigenetic repression of the
DUX4-fl mRNA, between individuals could account, at
least in part, for the wide variability in clinical presentation
of FSHD and similarly for the large number of asymptom-
atic individuals that fit the genetic criteria for FSHD1
[1,12,15,17,60,75,77]. Supporting this hypothesis, we found
that myogenic cells from these FSHD1-nonmanifesting
subjects have an intermediate epigenetic status at the
pathogenic distal 4q35 D4Z4 repeat that is not as relaxed
as that found in FSHD1 subjects manifesting weakness,
but not as repressed as that found in healthy control
subjects. In addition, DNA methylation levels at this
region correlate with clinical disease, showing significant
differences between the high methylation levels of healthy
controls, the intermediate levels of FSHD1-nonmanifesting
subjects, and the low levels of FSHD1-affected subjects.
These differences in DNA methylation levels were signifi-
cant in both a simple paired comparison between family
members and also in a mixed-effect model including all
samples (Figure 7).
This conclusion is in general agreement with a very re-
cent publication that utilized the methyl-sensitive Southern
blot method to investigate combined 4q and 10q D4Z4
DNA methylation levels at the proximal D4Z4 RU in
FSHD1-affected and asymptomatic/nonpenetrant (compar-
able to our nonmanifesting) individuals [25]. The authors
found that for those genetically FSHD1 subjects carrying
7 to 10 RUs at their shortest FSHD-permissive allele,
affected subjects have significantly less DNA methyla-
tion than predicted based on their 4q and 10q D4Z4
array sizes, while asymptomatic subjects do not. This
was interpreted as suggesting that for 7 to 10 RUs,
additional factors beyond array size are likely involved
in determining methylation levels, and clinical severity,
for those with borderline contracted alleles [25]. This
is in agreement with our finding that DNA methylation
levels on the contracted allele for nonmanifesting sub-
jects differ significantly from those for FSHD1-affected
and healthy controls, representing an intermediate level of
DNA methylation and epigenetic stability.
In light of this, there are several distinguishing features
of our study. We show that in FSHD1 subjects, DNA
methylation levels are altered specifically at the contracted
distal 4qA D4Z4 RU, and these alterations correlate with
disease severity. Importantly, our study goes beyond assay-
ing CpG methylation levels in these subjects and shows
that differential DNA methylation is functionally relevant,
correlating with general epigenetic repression or relax-
ation of the contracted 4q35 D4Z4 array, as assayed by
the expression of DUX4-fl. Myogenic cells from FSHD1-
nonmanifesting subjects, which have intermediate DNA
methylation at the distal 4q35 D4Z4 RU of the contracted
allele, exhibit greater repression of DUX4-fl than cells
from FSHD1-affected subjects, but less repression than
healthy control cells. Interestingly, there is also variability
in epigenetic repression among FSHD1-affected cells iso-
lated from different subjects, suggesting that an individ-
ual’s epigenetic status may be an important aspect of
clinical progression as well as disease presentation.
Considering that stable pathogenic DUX4-fl expression
originates in the distal D4Z4 RU and extends to the per-
missive A-type subtelomere, it stands to reason that the
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distal unit on the contracted 4qA allele is the most crit-
ical region to analyze. However, due to technical limita-
tions, all previous FSHD epigenetic studies had focused
either on the proximal, non-pathogenic 4q/10q D4Z4
RU or on the random analysis of all 4q/10q D4Z4 RUs
[4,20,25,50,51,76]. Our findings for this distal unit con-
firm earlier reports that hypomethylation in FSHD1 is
restricted to the contracted 4q allele in subjects disomic
for chromosome 4 type D4Z4 arrays [4] and moreover
offer improved resolution of the allele-specific DNA
methylation in two ways: first, in case of 4qA/4qA-L
genotypes, the methylation of the two alleles is mea-
sured independently; second, for 4qA/4qA genotypes
the measurement of methylation at multiple CpG sites
per molecule allows us to estimate average methylation
for each allele separately, rather than simply measuring
the average methylation for both alleles combined.
The epigenetic status of the 4q35 distal D4Z4 region,
as assayed by CpG methylation and DUX4-fl mRNA
induction in response to epigenetic drugs, not only differs
strongly between FSHD1-affected subjects and healthy
controls, and between FSHD1-nonmanifesting subjects
and healthy controls, but also differs between FSHD1-
affected and FSHD1-nonmanifesting subjects within fam-
ilies (Figures 7 and 9). In fact, DNA methylation analysis
of the distal 4qA D4Z4 RU could be used effectively as an
FSHD biomarker that distinguishes healthy subjects
from FSHD1-affected or FSHD1-nonmanifesting subjects.
Within families, analysis of DNA methylation alone can
generally distinguish between FSHD-affected and FSHD-
nonmanifesting relatives (Table 2; cohorts 15, 28, 29, 30,
46, 47, 48, and 49); however, the differences in methylation
levels between these genetically FSHD1 groups, while sig-
nificant at the population level, are smaller than the differ-
ences found between either of the groups and healthy
controls (Figure 7; Additional file 1: Table S2). Occasional
families in which differences between affected and nonma-
nifesting subjects are minimal (for example, cohort 43),
and variability in methylation levels between families, sug-
gest that epigenetic factors in addition to DNA methyla-
tion are involved in determining if a subject will be
clinically affected or disease nonmanifesting. Still, from a
diagnostic standpoint, when combined with a clinical
evaluation, this DNA methylation analysis will clearly
identify both FSHD1-affected and FSHD1-nonmanifesting
subjects from healthy (or non-FSHD) controls; the pres-
ence or absence of clinical symptoms consistent with
FSHD will differentiate the two hypomethylated groups.
The current diagnostic techniques for FSHD1 include
pulsed-field gel electrophoresis (PFGE) and molecular
combing [78,79]. These tests can be diagnostic for
FSHD1 in a patient with clinical symptoms if a con-
traction of the 4q35 D4Z4 array is identified ranging
between 1 and 10 D4Z4 RUs in cis with an A-type
subtelomere [15]; however, many people with RUs in
the higher range (7 to 10 D4Z4 RUs) do not show any
clinical manifestation of disease [20,33]. Therefore,
PFGE and molecular combing have much less prog-
nostic value for patients possessing D4Z4 contractions
at the high end of the FSHD1 range. However, the epi-
genetic status of the distal D4Z4 RU does correlate
with clinical manifestation and thus may be of more
prognostic value.
Our results contrast with a recent study by Gaillard
et al. [51], in which D4Z4 DNA methylation levels at
the 3′ end of D4Z4s (near our 4qA BSS assay) were
reported to be unchanged between FSHD1-affected,
asymptomatic, and control cells while DNA methyla-
tion changes at the D4Z4 5′ region (similar to our
DUX4 5′ BSS assay) could at best only distinguish
some FSHD1-affected cells from some unaffected cells,
grouping FSHD1 asymptomatic and healthy subjects
together. Surprisingly, the authors report D4Z4 DNA
methylation levels for FSHD1-asymptomatic cells that
were equivalent across the repeat to those found in
healthy control cells [51]. This discrepancy between
the two studies must be addressed, as it has significant
implications for both the clinic, with respect to diag-
nostics and potentially genetic counseling, and the lab,
with respect to understanding disease establishment
and mechanism as well as the design of therapeutic ap-
proaches. We have identified several critical technical
differences between these two studies that can reconcile
the data. First, we utilized familial cohorts of FSHD1 sub-
jects with or without disease manifestations who all have
D4Z4 repeat arrays of 5 to 8.5 RU (Table 2); the asymp-
tomatic subjects analyzed in the Gaillard et al. study
had 7 to 10 RU, which is the typical described range
for asymptomatic subjects [56,57,75,80]. In our analysis,
these FSHD1-affected subjects were analyzed separately
(Figure 7) from FSHD1-affected subjects without familial
nonmanifesting subjects, which tend to have smaller
contracted alleles with less DNA methylation that could
skew the analysis [20]. Additionally, our methylation ana-
lysis and interpretation of the DUX4 gene body is based
on the distal 4qA D4Z4 RU; thus, either 100% (4qA/B) or
approximately 50% (4qA/A) of the assayed chromosomes
are from the contracted 4qA array. Therefore, we have
specifically analyzed the methylation status of multiple
independent sequences from the FSHD1-associated
D4Z4, which is important because in FSHD1 only the
contracted 4q D4Z4 array shows epigenetic changes
[76]. In contrast, the Gaillard et al. study combined all
FSHD1-affected subjects, regardless of repeat size or
familial relationship, which potentially skewed the average
methylation for FSHD1-affected subjects to be lower than
if only FSHD1-affected subjects with similar repeat sizes
as their FSHD1-asymptomatic subjects were analyzed. In
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addition, the BSS assays utilized by Gaillard et al., similar
to our DUX4 5′ assay, do not distinguish between 4q and
10q D4Z4s and are therefore dominated by D4Z4 se-
quences derived from the expanded 4q/10q D4Z4 arrays,
with sizes averaging between 25 and 60 RUs and poten-
tially reaching over 100 RUs each, leaving D4Z4s from
the much smaller contracted FSHD1-associated 4q D4Z4
array (n ≤ 11) as a clear minority in, and potentially
altogether absent from, the assayed population. Therefore,
in the analysis of ten randomly amplified D4Z4s, the im-
pact of sequences from contracted 4qA alleles on the over-
all average methylation is expected to be small, and likely
within the range of normal variation for the other alleles;
thus, their analysis has severely limited statistical power. A
further complication involves the sequence variability of
BSS amplicons. 4q and 10q D4Z4 repeats have very few se-
quence polymorphisms [49], data supported by both of our
BSS assays, which both show >99.8% identity to the ex-
pected reference sequence (Figures 3, 4, 5, and 6; Additional
file 1: Figures S1 and S2), and others [52]. The presence of
numerous sequence polymorphisms affecting expected CpG
dinucleotides in the Gaillard et al. BSS analysis strongly sug-
gests that D4Z4s were amplified from non-4q/10q D4Z4
homologs [49]. Considering that these D4Z4 homologs
are not associated with FSHD or epigenetically altered
in the disease [49], any inclusion of these sequences
further complicates the methylation analysis, as it fur-
ther dilutes the signal from the contracted 4qA allele
(important for FSHD1) and also dilutes the signal from
combined 4q/10q alleles (important for FSHD2). Thus,
the discrepancy between our study and the Gaillard
et al. study is likely due to differences in 1) class of
subjects analyzed, 2) specificity of the BSS assays, and
3) statistical power of the analysis. It could be sug-
gested that differences might result from our analysis
being performed on fewer subjects; however, the fact
that the smaller number of samples in our study pro-
duced much clearer and more significant differences
actually highlights the power of our technique.
Overall, the DNA methylation results produced by our
analysis are consistent with the majority of published lit-
erature for FSHD1-affected subjects and healthy con-
trols, and the sequences analyzed are clearly specific for
the FSHD1-associated D4Z4 array. Therefore, we conclude
that FSHD1-nonmanifesting subjects have an intermediate
DNA methylation state at the distal D4Z4 on the contracted
4qA allele that distinguishes them from FSHD1 subjects
with muscle weakness and from healthy control subjects. In
addition, this intermediate state is functionally relevant in
that myocytes from FSHD1-nonmanifesting subjects exhibit
more stable epigenetic repression than their counterparts
from FSHD1-affected first-degree relatives. These different
epigenetic states of the distal 4qA D4Z4 repeat can be used
effectively as disease biomarkers that clearly distinguish
between FSHD1 subjects and healthy controls regard-
less of any familial relation [48], have clinical implica-
tions for FSHD diagnostics and therapy development,
and provide a basis for understanding the mechanism
of disease establishment. For example, our results sug-
gest that restoring even an intermediate level of DNA
methylation or small increases in heterochromatinization
of the D4Z4 array might be sufficient to lower DUX4-fl
expression to a non-pathogenic level. In addition, DNA
methylation has been found to decrease with age, and
these aging-related changes are not global within a cell;
some genomic regions change while others do not, and
the changes are tissue-specific [81-83]. It is not known if
the 4q35 D4Z4 array is susceptible to age-related changes
in DNA methylation, but it is possible that the initial epi-
genetic status of contracted D4Z4 arrays could affect age-
related demethylation and thus age of onset or severity of
disease.
FSHD1-sized D4Z4 arrays have characteristics of
metastable epialleles
The epigenome consists of DNA methylation, histone
post-translational modifications, and histone variants
throughout the genome that together form an integral
component of gene regulatory mechanisms [84-86]. Initially
established during development, the epigenome organizes
chromatin to restrict or facilitate the access of regulatory
factors to DNA. Epigenetic marks provide a mechanism for
regulatory memory that is passed on to subsequent cellular
generations and is vital for maintaining cell-type specific
patterns of expression and repression. The epigenetic mod-
ifications at the 4q35 D4Z4 array are established during
early development [30] and differ among individuals.
Potentially, variable aspects of the contracted D4Z4
array such as size or inherited DNA methylation pat-
terns, when combined with an individual’s expression
level or functional status of chromatin-modifying pro-
teins such as SMCHD1, could shift the establishment
of D4Z4 epigenetic repression in either direction. Similarly,
stress, nutrition, and exposure to other environmental
factors during critical points in development could in-
fluence the overall epigenetic state at the D4Z4 arrays.
Once established, the epigenetic state would persist
and provide protection from or susceptibility to aber-
rant DUX4-fl expression in muscle.
In addition to the strong influence of epigenetic regula-
tion, another important aspect of FSHD1 contracted D4Z4
regions is the variegated gene expression of DUX4-fl
mRNA, as both traits are characteristic of metastable
epialleles. Metastable epialleles (reviewed in [43,44]),
as opposed to traditional alleles, have variable expressivity
leading to phenotypic mosaicism between individuals, as
well as variegated cellular expression leading to pheno-
typic mosaicism between cells. This variable expression is
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not due to genetic heterogeneity, but rather is dependent
on the epigenetic state, which is established in a probabil-
istic manner during development and then maintained in
subsequent cellular generations. FSHD presents clinically
with great variability in age of onset, affected muscles, rate
of progression, and ultimate severity, even within families
and among monozygotic twins [87-91]. The variegated
DUX4-fl expression patterns in FSHD1 myogenic cells and
the variable clinical manifestation in genetically FSHD1 indi-
viduals appear consistent with the FSHD1-associated DUX4
allele functioning as a metastable epiallele [8].
Conclusions
FSHD is characterized by epigenetic dysregulation [8]. Here,
we show that in the context of an FSHD1 disease-permissive
allele, consisting of a contracted 4q D4Z4 in cis with a per-
missive A-type subtelomere, the epigenetic state of the
4q35 array is dominant over the genetic state in terms of
disease outcome (Figure 10). Our DNA methylation ana-
lysis has uncovered distinct epigenetic states at the distal
4q D4Z4 array for unaffected, FSHD1-affected, and FSHD1-
nonmanifesting subjects and has the potential to be used for
diagnostic purposes. These different epigenetic states affect
the stability of gene repression and potentially the splicing of
the pathogenic DUX4-fl isoform. In addition, the contracted
4qA allele in genetically FSHD1 subjects has the characteris-
tics of a metastable epiallele, which may impact disease
establishment and progression, and provide an avenue
to therapy via epigenetic manipulation.
Methods
Human subjects
This study was approved by the Johns Hopkins School
of Medicine Institutional Review Board. Families with
a member diagnosed with FSHD1 were invited to par-
ticipate. Individuals were genotyped and considered to
be affected with FSHD1 if a 4qA EcoRI/BlnI fragment <35
kb was identified using genomic DNAs isolated from per-
ipheral blood mononuclear cells (PBMC) or considered to
be healthy controls if they lacked a contracted 4qA allele
(Additional file 1: Table S1). Haplotypes for both 4q alleles
were determined for all subjects, as described [17]. All
FSHD1 individuals were examined by an experienced
neuromuscular physician (KRW). FSHD1 individuals were
further characterized as ‘manifesting’ disease (affected) if
they had weakness in the distribution classic for FSHD
Figure 10 FSHD1-affected, FSHD1-nonmanifesting, FSHD2, and healthy subjects are characterized by distinct states of epigenetic
susceptibility to DUX4-fl expression. Model for the different epigenetic states that distinguish healthy vs. FSHD1-affected vs. nonmanifesting
vs. FSHD2 subjects. Healthy, unaffected subjects are characterized by stable repression of the distal pathogenic D4Z4 repeat, as indicated by DNA
hypermethylation and chromatin compaction. Cells from these subjects express very low or undetectable levels of DUX4-fl, and are refractory to
epigenetic induction of DUX4-fl. Cells from FSHD1-affected subjects display de-repression at the distal pathogenic D4Z4, as indicated by DNA
hypomethylation and loss of chromatin compaction. These cells express detectable DUX4-fl, which is further induced upon treatment with
epigenetic drugs. Cells from FSHD1-nonmanifesting subjects display an intermediate level of repression at the distal pathogenic D4Z4, as indicated
by levels of DNA methylation and DUX4-fl inducibility which fall between those of FSHD1-affected and healthy, unaffected subjects. Despite lacking a
contracted D4Z4 allele, cells from FSHD2 subjects are distinguished by severe hypomethylation at D4Z4 arrays, indicating a pronounced de-repression
in these regions, which results in detectable expression of DUX4-fl. Interestingly, the shortest permissive 4q array in FSHD2 subjects tends to be shorter
(approximately 16 RU) on average than the shortest 4q array in the healthy population (approximately 24 RU) [18,25]. *In genetically FSHD1 subjects,
only the contracted 4q D4Z4 is hypomethylated; **In FSHD2 subjects, both 4q and 10q D4Z4 arrays are hypomethylated. Refer to text for more details.
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(for example, face, shoulder girdle, and biceps) or ‘nonma-
nifesting’ if they had full strength in this distribution.
Clinical samples
Myogenic cells derived from the biceps muscles of genet-
ically FSHD1 subjects (03Abic, 07Abic, 09Abic, 12Abic,
17Abic, 15Abic, 15Bbic, 16Abic, 19Abic, 21Abic, 28Abic,
28Bbic, 29Abic, 29Bbic, 30Abic, and 30Bbic) and their
healthy unaffected first-degree relatives (03Ubic, 07Ubic,
09Ubic, 12Ubic, 16Ubic, 17Ubic, 17Vbic, 19Ubic, and
21Ubic) were used in this study (as previously de-
scribed, Homma et al. [45]). All cells were obtained from
the Paul. D. Wellstone Muscular Dystrophy CRC for
FSHD at the University of Massachusetts Medical School,
Worcester, MA (http://www.umassmed.edu/wellstone/).
Myogenic cells were selected by FACS for CD56 expres-
sion such that all cultures were >90% desmin-positive
[33,45]. Myogenic cells were grown on gelatin-coated
dishes in high serum growth medium for proliferation
then switched to low serum differentiation medium to
induce myotube formation [33,45]. As described [92],
proliferation of primary cultures of human myogenic
cells began to slow at 55 to 60 population doublings as
cells neared replicative limits. Therefore, all cells were
used at <30 population doublings, except where indi-
cated in subculturing experiments when cultures were
examined at up to 47 population doublings. For all
subjects in cohorts 39, 41, 43, 46, 47, 48, 49, and 51,
DNA methylation analysis was performed on genomic
DNAs isolated from PBMCs collected under IRB-approved
protocols at the appropriate institution.
Serial subcultures
Myogenic cells were cultured in growth medium on
gelatin-coated plates to approximately 80% confluence,
at which time cells were counted to calculate population
doublings and passaged at 1:10 dilution. At each passage,
cells were cultured in parallel on one 100-mm plate and
one gelatin-coated four-well chamber slide. The culture
in each plate was used to maintain myoblasts in growth
medium for additional passaging, whereas the culture in
each chamber slide was used to generate differentiated
myotubes, which were analyzed for DUX4-FL and MyHC
expression after 4 days in differentiation medium.
Drug treatment
Stock solutions of 100 mM 5-Aza-2′-deoxycytidine/
Decitabine, (Sigma-Aldrich A3656, St. Louis, MO, USA)
in DMSO, 5 mM Trichostatin A solution (TSA, Sigma-
Aldrich T1952), and 10 mM chaetocin (Sigma-Aldrich
C9492) in DMSO were stored at −20°C and diluted with
PBS just before adding to the culture. To minimize cultur-
ing artifacts, low passage (<30 population doublings) myo-
blast cultures were used for all experiments and culture
pairs for affected vs. healthy or affected vs. nonmanifesting
were within 1 passage of each other in all instances.
Myoblasts were seeded on collagen-coated plates at a cell
density of 1.6 × 103/cm2. Starting the following day,
Decitabine (5 μM final concentration) was added daily
for a total of 3 days. When used, TSA (200 nM final
concentration) or chaetocin (50 nM final concentra-
tion) was added to the cells for the last 24 h prior to
sampling.
Immunostaining
Myogenic cell cultures were fixed and co-immunostained
for DUX4-FL and myosin heavy chain (MyHC). DUX4-FL
was detected with either P4H2 mouse mAb as described
[33] or rabbit mAb E5-5 (Epitomics, Burlingame, CA,
USA) as described [47]. MyHC isoforms were detected
with either mouse mAb MF20 or mouse mAb F59 [93],
which were obtained from the Developmental Studies
Hybridoma Bank developed under the auspices of the
NICHD and maintained by the University of Iowa,
Department of Biology, Iowa City, IA, USA. Nuclei were
stained with bisbenzimide. The number of DUX4-FL-
positive nuclei was determined from manually scan-
ning the entire culture area. The number of nuclei in
MyHC-positive cells and the total number of nuclei
was approximated for each cell strain by counting 10
random fields of known area at 10X magnification and
extrapolating to the total area of the well. Nuclei of
60,000 to 150,000 were screened for each cell culture.
Cultures were imaged with a Nikon E800 fluorescence
microscope with Spot camera and software, version 4.6
(Diagnostic Instruments, Inc., Sterling Heights, MI, USA).
BSS DNA methylation analysis
For all subjects in cohorts 03, 07, 09, 12, 15, 16, 17, 19,
21, 28, 29, and 30, DNA methylation analysis was per-
formed on genomic DNAs isolated from myocytes. For
all subjects in cohorts 39, 41, 43, 46, 47, 48, 49, and 51,
DNA methylation analysis was performed on genomic
DNAs isolated from PBMCs. DNA methylation of the
4qA and 4qA-L distal regions was analyzed using the
4qA BSS and 4qA-L BSS assays, as described [23,48].
BSS analysis of 59 CpGs in the DUX4 promoter region
(DUX4 5′ BSS assay) of 4q and 10q D4Z4 repeats was
performed using primers BSS167F: TTTTGGGTTGGG
TGGAGATTTT and BSS1036R: AACACCRTACCRA
ACTTACACCCTT, then followed by nested PCR with
BSS475F: TTAGGAGGGAGGGAGGGAGGTAG and
BSS1036R using 10% of the first PCR product. PCR
products were cloned into the pGEM-T Easy vector
(Promega, Madison, WI, USA), sequenced, and analyzed
using web-based analysis software BISMA (http://bio-
chem.jacobs-university.de/BDPC/BISMA/) [94] with the
default parameters.
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Allele-specific DNA methylation estimation
The percentage of methylated CpG sites in a region can
vary between alleles and can also vary between cells for
the same allele. To prevent high methylation on the non-
contracted 4qA allele from masking or diluting the signal
for reduced methylation on the contracted 4qA allele
(a weakness with methods that only measure overall
average methylation [20]), we wish to estimate methy-
lation for just the allele with lower methylation. For
the purpose of distinguishing FSHD1-affected subjects
from healthy controls, we proposed a simple score, the
lower quartile (Q1) of percent methylation of all se-
quenced clones [48]. If two alleles have non-overlapping
ranges of methylation and are represented in roughly
equal proportions, this will approximate the median for
just the allele with lower methylation. But if two alleles
have overlapping ranges of methylation, Q1 is biased
toward underestimating the median for the allele with
lower methylation. Likewise, akin to the extreme cases
in which two alleles have identical distributions, Q1
will underestimate the median methylation in cases
where only one allele is amplified by the PCR assay, for
example, if the other allele is a 4B, 4A-L, or 4A166
haplotype, which may not be known in advance. To reduce
this bias, here we use a parametric model-based method for
estimating allele-specific methylation.
The distribution of counts of methylated CpG sites
across clones is not satisfactorily modeled by a binomial
distribution, as the observed variance is typically approxi-
mately four times greater than that of a binomial distribu-
tion with the same mean and N (where N is the number
of CpG sites; N = 56 for the 4qA assay, and N = 30 for the
4qA-L assay) (Additional file 1: Figure S3). This overdis-
persion is not simply due to the presence of two alleles
with different methylation probabilities, as it is also
seen when restricting the analysis to samples for which
all clones arise from a single 4qA allele (for example,
4qA/4qB genotypes). This overdispersion can also not
be addressed by allowing site-specific methylation prob-
abilities for each CpG site (as in [95]) since by a convexity
argument the resulting Poisson binomial distribution has
variance at most as large as a standard binomial distribu-
tion with the same mean and same N.
To account for the overdispersion, the number of
methylated CpGs for each allele (i = 1, 2) was modeled
as a beta binomial distribution, where each clone (indexed
by j) from the allele has an average methylation probability
pij drawn independently from a beta distribution with
parameters ai and bi, and the observed number of
methylated CpGs follows a binomial distribution with
probability pij and sample size N. This distribution has
the expected average CpG methylation fraction ai/(ai + bi),
with variance decreasing as ai + bi increases, approaching a
binomial distribution in the limit of large ai + bi. A
Bayesian two-component mixture model was used to infer
the parameters of the beta binomial distributions for each
of the alleles and to compute the posterior probability of
each sequence having originated from each allele, based on
the observed methylation data. Note that unlike refs
[95,96] we model just the total count of methylated CpGs,
and not site-specific methylation probabilities; we also dif-
fer in using full Bayesian inference rather than maximum
likelihood estimation.
The beta binomials were re-parameterized by ri =
log(ai/bi) and si = ai + bi for i =1, 2. To break the sym-
metry between the two alleles and impose a labeling of
alleles so that r1 ≤ r2 we use a N(μ = 0, σ = 2) prior for the
average of r1 and r2, and a zero-inflated gamma(k = 1, β
= 0.5) distribution as a prior for the difference d = r1 −
r2 ≥ 0. The zero-inflation puts a 0.5 prior probability
mass on the difference being exactly zero, so the model
can be used for 4qA/4qA, 4qA/4qB, or unknown geno-
types. One could also adjust the prior based on known
genotype data, or use the posterior probability that d >
0 as a measure of evidence for allele-specific methyla-
tion. We use a gamma(k = 1, β = 0.025) prior for s1 and
s2. A small fraction of sequences are missing methyla-
tion data at a small number (1 to 3) of sites; N was de-
creased accordingly for these sequences. Posterior means
for the parameters of interest were computed using Mar-
kov Chain Monte Carlo (MCMC), with the Rjags (v3-14)
interface to the JAGS (v3.3.0) sampler. We used 1,000
MCMC steps for burn-in, followed by 30,000 MCMC
steps for inference; convergence was monitored with the
Gelman-Rubin diagnostic (PFSR < 1.01) [97] based on
three chains run in parallel.
Additional file 1: Figure S4 (top) shows an example
(16Abic) in which clones clearly separate into two clus-
ters with distinct methylation percentages, and the two
components of the mixture correspond to these two
clusters, while allowing for slight deviations from 50% of
clones in each cluster; Additional file 1: Figure S4 (bottom)
shows an example (17Ubic) in which the clones do not
clearly separate into two clusters, and the two estimated
mixture components are nearly the same, with the allele of
origin ambiguous for all clones; as the genotype of this
sample is 4qA/4qB, we do not expect to see evidence of
allele-specific methylation here. Bayesian allele-specific es-
timates depend on the prior probability distributions speci-
fied, but we confirmed that the reported differences
between groups remained significant for other choices
of parameters for the priors (twofold increase or de-
crease for standard deviation σ of normal prior and
rate parameters β for gamma priors).
Comparisons of DNA methylation between disease classes
For comparisons of DUX4 gene body methylation
between FSHD-affected, nonmanifesting, and control
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samples, we first used the procedure described above to
estimate the average methylation percentage for the 4A
allele with lowest average methylation. For FSHD1 sam-
ples, this is expected to be the contracted D4Z4 4A al-
lele. We use the same procedure for control samples
with no contracted alleles for uniformity. We likewise
use this procedure for samples believed to have only one
amplified 4A allele; in such cases, the two allele-specific
methylation estimates are typically quite close (within a
percent or two, although larger deviations did sometimes
occur, particularly in blood, perhaps representing in-
creased mixing of multiple cell lineages).
We used a linear mixed effect (LME) model to fit the
values y = log(a/b) for each sample, with fixed effects
for cell type (myocyte or blood) and disease class (FSHD-
affected, nonmanifesting, or control), including interac-
tions between them, and a random effect for family. We
also included an additive fixed effect for assay type (4qA
or 4qA-L), as these assess different CpG sites that may
have different baseline methylation percentages; indeed,
for the 4qA assay, there are variations in CpG methylation
probabilities across the length of the sequence, with
the central third of the CpG sites typically showing
less methylation than the first third (Additional file 1:
Figure S5). Because we had limited 4qA-L data, we did
not attempt to model interactions between assay type
and cell type or disease class here. For sample 17A,
which had both 4qA and 4qA-L alleles, we used the
4qA assay as it gave a smaller value of y. This corre-
sponded to the shorter allele (19 kb vs. 87 kb) as desired;
however, in the absence of genotyping data, a known base-
line difference in methylation between 4qA and 4qA-L
alleles could be adjusted for in deciding which should
be regarded as the less methylated allele.
Note that y is equal to the log odds ratio log(p/(1 − p)),
where p is the average fraction of CpG sites methylated.
This logit transformation avoids the compression of values
near p = 0 and p = 1. Estimated means and confidence in-
tervals were transformed back to percentages in figures
and tables. Models were fit using the R package lme4
(v1.1-7), and likelihood ratio tests were used for assessing
significance. Because FSHD-affected subjects with nonma-
nifesting first-degree relatives may as a group differ from
other FSHD subjects (due, for example, to nonmanifesting
individuals tending to have borderline D4Z4 repeat
lengths), we performed these tests with FSHD subjects
divided into two subgroups, allowing nonmanifesting
subjects to be compared with just their affected relatives
(subgroup FSHD(b)) in a joint model that also includes
the other FSHD cases (subgroup FSHD(a)) (for these
particular FSHD samples, the two subgroups did not
differ significantly; P = 0.29 by LRT). Likelihood ratios
were computed between the full model and models
with two of the four disease-call subgroups collapsed,
or with the two cell types collapsed, with the lme4
function ‘anova’.
qRT-PCR
Total RNAs were extracted using Trizol (Invitrogen,
Carlsbad, CA, USA) and purified using the RNeasy Mini
kit (Qiagen, Limburg, Netherlands) after on-column
DNase I digestion. Total RNA (2 μg) was used for
cDNA synthesis using Superscript III Reverse Transcript-
ase (Invitrogen), and 200 ng of cDNA were used for
DUX4-fl qPCR analysis as described [33]. All data were
normalized to levels of 18S rRNA [98]. Oligonucleotide
primer sequences are provided in [33]. For the analysis of
ANKRD1 mRNA expression, 40 ng of cDNA were used
with primers hANKRD1 For: GCCTACGTTTCTGAAG
GCTG and Rev: GTGGATTCAAGCATATCACGGAA.
Additional file
Additional file 1: Supplementary data. Table S1. Characteristics of cell
donors. Table S2. Summary of percent methylation. Figure S1. FSHD1-affected
subjects are distinguished by lower levels of DNA methylation than healthy
subjects at the 4q/10q D4Z4 5′ region. Figure S2. FSHD1-nonmanifesting
subjects are distinguished by higher levels of DNA methylation than
FSHD1-affected subjects at the 4q/10q D4Z4 5′ region. Figure S3.
Within-sample variability in the number of methylated CpGs in the
DUX4 gene body is greater than expected for a binomial distribution.
Figure S4. Beta-binomial mixture model for the 4qA BSS assay. Figure S5.
CpG methylation probabilities vary across the sequence in the 4qA BSS assay.
Figure S6. Drug treatments have similar effects on control gene expression in
FSHD1-affected and unaffected myocytes.
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